文献速递骨质疏松与钙磷/甲状旁腺

甲状旁腺癌:从分子发病机制到多学科管理

Parathyroid carcinoma: from molecular pathogenesis to multidisciplinary management.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本文综述甲状旁腺癌的分子发病机制、诊断、影像、治疗与预后;该病主要由CDC73突变及parafibromin表达缺失驱动,诊断困难,整块切除加同侧甲状腺叶切除为标准术式,复发率23%至65%需终身随访,多学科管理至关重要。

要点

  • 显著高钙血症、PTH升高、颈部可触及肿块或喉返神经麻痹时应警惕甲状旁腺癌。
  • 整块切除加同侧甲状腺叶切除是标准手术方式,复发率23%至65%需终身随访。
  • 靶向治疗与免疫治疗在晚期病例显示前景,但证据薄弱。

核心结论

  • 甲状旁腺癌罕见,主要驱动因素为CDC73突变伴parafibromin表达缺失。
  • 多学科管理在专科中心对优化结局至关重要。

研究设计与样本

  • 综述总结甲状旁腺癌分子发病机制、诊断、影像、管理与预后的当前知识。

主要发现

  • 甲状旁腺癌占原发性甲状旁腺功能亢进症病例的<1%。
  • PI3K/AKT/mTOR与Wnt通路改变在甲状旁腺癌中显示新兴作用。
  • 复发率为23%至65%。
  • 预后因素包括手术方式、术后缓解、Ki-67指数、parafibromin状态及mTOR激活。

关键数值与推荐

  • 临床怀疑依据包括显著高钙血症、PTH升高、颈部可触及肿块或喉返神经麻痹。
  • 影像学包括颈部超声、99mTc-sestamibi、4D-CT及[18F]氟胆碱PET/CT辅助定位与转移检测。
  • 标准手术方式为整块切除加同侧甲状腺叶切除。
  • 传统药物治疗有助于降低血清钙水平;放疗与化疗疗效有限。

临床怎么用

  • 对疑似病例应结合临床怀疑与影像学定位,首选整块切除加同侧甲状腺叶切除。
  • 传统药物可用于降低血清钙,靶向与免疫治疗可用于晚期但证据薄弱。
  • 因复发率高,需终身随访并由专科中心多学科管理。

局限性

  • 靶向治疗与免疫治疗在晚期疾病中的证据薄弱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Parathyroid carcinoma (PC) is a rare malignancy accounting for <1% of primary hyperparathyroidism cases. This review summarizes current knowledge on its molecular pathogenesis, diagnosis, imaging, management and prognosis. PC is driven primarily by CDC73 mutations with loss of parafibromin expression, with emerging roles for PI3K/AKT/mTOR and Wnt pathway alterations. Its diagnosis remains challenging. Clinical suspicion should arise with marked hypercalcemia, elevated PTH, palpable neck mass or recurrent laryngeal nerve palsy. Imaging modalities including cervical ultrasound, 99mTc-sestamibi, 4D-CT, and [18F]fluorocholine PET/CT aid localization and metastasis detection. En bloc resection with ipsilateral thyroid lobectomy is the standard approach. Traditional medical therapies are helpful in reducing serum calcium level. Radiotherapy and chemotherapy have limited efficacy. Targeted therapies and immunotherapy show promise in advanced disease, however, the such evidence is weak. Recurrence rates of 23% to 65% mandate lifelong follow-up. Prognostic factors include surgical approach, postoperative remission, Ki-67 index, as well as parafibromin status and mTOR activation. Multidisciplinary management in specialized centers is critical for optimizing outcomes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Song JX, Yang YY, Zhou JX, et al. Parathyroid carcinoma: from molecular pathogenesis to multidisciplinary management. J Clin Endocrinol Metab. 2026. PMID: 42400268. doi:10.1210/clinem/dgag266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。